What is B. Riley’s Forecast for MDGL Q3 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities research analysts at B. Riley upped their Q3 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued to clients and investors on Monday, August 18th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of ($0.81) per share for the quarter, up from their prior estimate of ($2.22). B. Riley currently has a “Buy” rating and a $460.00 price target on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q4 2025 earnings at $0.17 EPS, FY2025 earnings at ($5.76) EPS, FY2026 earnings at $10.72 EPS, FY2027 earnings at $19.38 EPS and FY2028 earnings at $39.84 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.48) by $1.58. The firm had revenue of $212.80 million during the quarter, compared to analyst estimates of $158.94 million. Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%.Madrigal Pharmaceuticals’s quarterly revenue was up 1357.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($7.10) earnings per share.

A number of other analysts have also issued reports on the company. UBS Group reiterated a “buy” rating and issued a $523.00 price target (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a report on Tuesday, August 12th. JMP Securities upped their target price on Madrigal Pharmaceuticals from $483.00 to $485.00 and gave the stock a “market outperform” rating in a report on Wednesday. Wall Street Zen upgraded Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 5th. Finally, Canaccord Genuity Group upped their target price on Madrigal Pharmaceuticals from $420.00 to $428.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $445.71.

Madrigal Pharmaceuticals Stock Up 3.2%

Shares of NASDAQ MDGL opened at $391.66 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.78 and a current ratio of 5.11. The firm has a market capitalization of $8.69 billion, a price-to-earnings ratio of -30.48 and a beta of -1.02. The stock has a 50 day moving average price of $316.47 and a 200 day moving average price of $315.55. Madrigal Pharmaceuticals has a 52-week low of $200.63 and a 52-week high of $393.77.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several hedge funds have recently made changes to their positions in MDGL. Adage Capital Partners GP L.L.C. increased its position in shares of Madrigal Pharmaceuticals by 96.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 376,163 shares of the biopharmaceutical company’s stock valued at $113,842,000 after acquiring an additional 184,554 shares during the period. Norges Bank acquired a new stake in Madrigal Pharmaceuticals during the 2nd quarter worth about $53,406,000. Woodline Partners LP grew its position in Madrigal Pharmaceuticals by 110.2% during the 4th quarter. Woodline Partners LP now owns 309,117 shares of the biopharmaceutical company’s stock worth $95,384,000 after purchasing an additional 162,027 shares during the period. Hood River Capital Management LLC acquired a new stake in Madrigal Pharmaceuticals during the 4th quarter worth about $39,447,000. Finally, MPM Bioimpact LLC acquired a new stake in Madrigal Pharmaceuticals during the 1st quarter worth about $33,260,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Madrigal Pharmaceuticals news, Director Bros. Advisors Lp Baker acquired 59,901 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was purchased at an average price of $385.16 per share, for a total transaction of $23,071,469.16. Following the acquisition, the director owned 1,947,968 shares in the company, valued at approximately $750,279,354.88. This trade represents a 3.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kenneth Bate sold 10,000 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $365.20, for a total value of $3,652,000.00. Following the sale, the director owned 2,627 shares of the company’s stock, valued at approximately $959,380.40. This represents a 79.20% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 165,683 shares of company stock worth $61,921,142 and have sold 294,124 shares worth $106,413,560. 21.50% of the stock is currently owned by company insiders.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.